Choroidal Neovascularization Market by Treatment Type (Anti-Vegf Therapy, Combination Therapy, Photodynamic Therapy), Drug Class (Fusion Proteins, Monoclonal Antibodies), Disease Type, Lesion Type, Line Of Therapy, Distribution Channel, End User - Global
Description
The Choroidal Neovascularization Market was valued at USD 6.38 billion in 2024 and is projected to grow to USD 6.88 billion in 2025, with a CAGR of 7.85%, reaching USD 11.69 billion by 2032.
Framing the clinical imperatives and market forces shaping choroidal neovascularization management with a focus on preserving vision and optimizing care delivery
Choroidal neovascularization (CNV) represents a focal point of innovation and clinical urgency within retinal disease management, driven by the imperative to preserve vision and mitigate progressive visual decline. Over the past decade, treatments targeting vascular endothelial growth factor pathways have reshaped therapeutic practice, yet unmet needs persist in durability of response, safety profiles, real-world accessibility, and affordability. This introduction frames the evolving clinical, commercial, and regulatory contexts that are influencing care pathways for patients with neovascular age-related macular degeneration and pathologic myopia.
Clinicians and payers alike are grappling with treatment paradigms that balance injection frequency, anatomical outcomes, and patient adherence. At the same time, novel modalities and combination strategies are emerging to extend durability, reduce treatment burden, and address subpopulations with refractory disease or specific lesion morphologies. Consequently, stakeholders from device and pharmaceutical sponsors to providers and health systems must align around evidence generation, health economics, and delivery models that support sustained patient benefit. This section establishes the clinical imperatives and market forces that underpin the subsequent analysis, setting expectations for how therapeutic innovations and system-level shifts will influence clinical practice and commercial strategy.
Exploring how therapeutic innovation, advanced imaging, combination strategies, and real-world evidence are reshaping clinical and commercial dynamics in CNV care
The landscape for CNV is undergoing transformative shifts driven by converging scientific advances, evolving standards of care, and shifting payer expectations. Biologic engineering has enabled more potent and longer-acting anti-VEGF agents while refinements in formulation and delivery are moving the field toward less frequent dosing and potentially sustained-release approaches. These scientific developments are complemented by advances in imaging and disease monitoring, where high-resolution OCT and AI-assisted analytics are enabling earlier detection of disease activity and more personalized retreatment schedules.
Simultaneously, combination therapy strategies that pair photodynamic mechanisms with VEGF inhibition are being revisited to address specific lesion subtypes and to potentially reduce overall treatment burden. Real-world evidence is increasingly informing label expansions and reimbursement discussions, influencing adoption patterns across hospital systems and ambulatory settings. On the commercial front, manufacturers are adapting launch strategies to emphasize comparative effectiveness and differentiated value propositions, while providers are optimizing care delivery across hospital pharmacies, retail channels, and specialty clinics. Taken together, these shifts are expanding therapeutic choices and prompting stakeholders to reassess clinical pathways, evidence needs, and value communication.
Assessing the strategic implications of evolving U.S. tariff environments on supply chain resilience, sourcing strategies, and access dynamics within CNV treatment channels
Policy changes and tariff scenarios within the United States have become material considerations for supply chain planning and pricing strategies in ophthalmology. Adjustments to import tariffs on pharmaceutical components and medical devices influence manufacturing location decisions, packaging, and distribution economics, requiring manufacturers to reevaluate sourcing strategies and contract terms to preserve margin and maintain predictable supply to providers.
As a result, there is greater emphasis on nearshoring options, regional manufacturing partnerships, and supply chain redundancy to mitigate exposure to tariff-driven cost volatility. Payers and providers are increasingly attentive to total cost of care and may shift procurement preferences toward therapies that demonstrate clear economic and clinical value in the context of higher logistics costs. For companies, proactive scenario planning that models tariff impacts across distribution channels and end users-hospital pharmacies, retail pharmacies, ambulatory surgical centers, and ophthalmology clinics-can inform pricing approaches, rebate structures, and contracting negotiations. In this environment, transparent communication about cost drivers and collaborative approaches to patient access programs are essential to sustain utilization and support adherence to guideline-driven care.
Delivering strategic clarity through treatment, drug class, disease, lesion, therapy line, distribution, and end-user segmentation insights that inform targeting and development
A nuanced understanding of segmentation is critical to target clinical development and commercial efforts effectively. Treatment type remains foundational, with anti-VEGF therapy representing a core category inclusive of agents such as aflibercept, bevacizumab, brolucizumab, conbercept, and ranibizumab, each offering distinct efficacy, durability, and safety considerations. Combination approaches that integrate photodynamic therapy with anti-VEGF are being explored to address select lesion morphologies and to potentially reduce treatment frequency, while standalone photodynamic therapy using verteporfin retains specific niche indications.
Drug class distinctions between fusion proteins and monoclonal antibodies influence mechanism of action, immunogenicity risk, and production platforms, shaping development strategies and regulatory positioning. Disease-type segmentation separates clinical approaches for neovascular age-related macular degeneration and pathologic myopia, which present different natural histories, patient demographics, and outcome priorities. Lesion type-classic, mixed, and occult CNV-affects therapeutic responsiveness and imaging-guided decision-making. Line-of-therapy considerations spanning first, second, and third lines dictate clinical trial design and commercial messaging, as refractory populations may require differentiated value propositions. Finally, distribution channels and end-user environments, from hospital and retail pharmacies to ambulatory surgical centers and ophthalmology clinics, each present unique procurement behaviors, reimbursement pathways, and operational constraints that must be aligned with market access strategies.
Unpacking the distinctive regional drivers across the Americas, Europe–Middle East–Africa, and Asia–Pacific that influence access, reimbursement, and adoption pathways in CNV care
Regional dynamics play a pivotal role in shaping clinical adoption, regulatory pathways, and commercial approaches. In the Americas, care delivery is driven by a combination of academic referral centers, community ophthalmology practices, and integrated health systems that prioritize evidence-based adoption of long-acting therapies and cost-effectiveness in procurement decisions. Reimbursement frameworks and payer negotiations heavily influence formulary placement and access programs, while real-world registries and longitudinal datasets increasingly inform local practice.
Across Europe, the Middle East, and Africa, heterogeneity in regulatory environments and health system structures yields a mosaic of uptake patterns; centralized procurement in some markets contrasts with decentralized provider-driven adoption in others, necessitating flexible market-entry and pricing strategies. In the Asia-Pacific region, rapid demographic aging, expanding private and public ophthalmic infrastructure, and emergent local biotherapeutic development are accelerating demand for advanced CNV therapies, while regional manufacturing capacity and regulatory harmonization efforts are shaping supply dynamics. Each geography presents distinct clinical priorities, distribution complexities, and stakeholder expectations that should guide tailored launch plans and evidence generation strategies.
Examining competitive differentiation, partnership strategies, and evidence priorities among leading companies to advance therapeutic advantage in CNV management
Competitive dynamics in the CNV therapeutic area are characterized by a mix of established biologics, emergent long-acting agents, and evolving combination strategies, with companies differentiating through clinical performance, dosing convenience, and demonstrated value in real-world settings. Market participants are prioritizing investments in formulation science, sustained-release delivery systems, and head-to-head clinical comparisons to substantiate claims of extended durability and improved anatomical outcomes.
Strategic partnerships, licensing arrangements, and co-development agreements are increasingly common as firms seek complementary capabilities in biologics manufacturing, ophthalmic device delivery, and regional commercialization. Portfolio decisions are being informed by mechanistic differentiation between fusion proteins and monoclonal antibodies, as well as by evidence addressing lesion subtype responsiveness and treatment-resistant populations. Additionally, organizational focus on health economics, outcomes research, and payer engagement is growing, reflecting the need to align clinical innovation with demonstrable cost-effectiveness and patient-centric endpoints to secure favorable reimbursement and long-term uptake.
Implementing targeted clinical evidence, supply resilience, and partnership-driven commercialization tactics to accelerate access and distinguish therapeutic offerings in CNV care
Industry leaders should pursue a set of actionable moves to navigate scientific, commercial, and policy complexities while accelerating patient access to effective treatments. First, aligning clinical development with robust real-world evidence generation will strengthen health economic arguments and support reimbursement discussions; studies should be designed to capture durability, quality-of-life, and resource utilization outcomes that matter to payers and providers. Second, optimizing manufacturing and supply chain footprints to address tariff-induced volatility will reduce exposure to cost shocks and support reliable distribution across hospital and retail channels.
Third, segmenting go-to-market strategies by disease type, lesion morphology, and line of therapy will enable targeted messaging and clinical trial design, ultimately improving conversion among ophthalmology clinics, ambulatory surgical centers, and hospital systems. Fourth, forming strategic alliances-whether for delivery technologies, regional commercialization, or data analytics-can accelerate time-to-market and broaden access. Finally, investing in provider education, digital monitoring tools, and patient support programs will enhance adherence, demonstrate real-world value, and differentiate offerings in a crowded therapeutic landscape.
Outlining a rigorous, multi-source research methodology combining clinical evidence synthesis, expert engagement, and policy analysis to ensure transparent and actionable findings
The research methodology underpinning this analysis combined systematic literature review, synthesis of peer-reviewed clinical data, expert interviews with retina specialists and health system decision-makers, and an assessment of regulatory and reimbursement policy developments up to mid-2024. Clinical efficacy and safety insights were triangulated from randomized controlled trials, registries, and post-marketing surveillance reports to ensure a comprehensive view of therapeutic performance across lesion types and patient subgroups.
Commercial and access conclusions were informed by interviews with commercial leaders, formulary decision-makers, and supply chain specialists, augmented by review of public regulatory filings and guidance documents. Segmentation analysis was conducted by mapping treatment types, drug classes, disease types, lesion morphology, lines of therapy, distribution channels, and end-user settings to observed clinical practices and procurement behaviors. Where applicable, sensitivity checks and scenario analyses were used to assess implications of policy shifts and supply chain changes. The methodology prioritized transparency and reproducibility, enabling stakeholders to trace conclusions back to primary evidence and expert input.
Concluding synthesis emphasizing integration of clinical innovation, real-world evidence, and operational resilience as critical levers for long-term success in CNV management
In conclusion, choroidal neovascularization management is at a strategic inflection point where therapeutic innovations, evidence generation, and supply chain resilience converge to define future care pathways. Advances in anti-VEGF therapies and combination approaches are expanding clinical options, while imaging and data-driven monitoring enable more personalized and efficient retreatment strategies. At the same time, policy shifts and tariff considerations are prompting stakeholders to rethink sourcing and distribution to ensure uninterrupted access and sustainable economics.
For decision-makers across clinical, commercial, and policy domains, the imperative is to integrate high-quality clinical data with real-world outcomes, align development and launch plans to segmented patient needs, and build operational agility into manufacturing and distribution networks. By doing so, organizations can improve patient outcomes, demonstrate value to payers, and secure a competitive position in an increasingly complex and dynamic landscape.
Note: PDF & Excel + Online Access - 1 Year
Framing the clinical imperatives and market forces shaping choroidal neovascularization management with a focus on preserving vision and optimizing care delivery
Choroidal neovascularization (CNV) represents a focal point of innovation and clinical urgency within retinal disease management, driven by the imperative to preserve vision and mitigate progressive visual decline. Over the past decade, treatments targeting vascular endothelial growth factor pathways have reshaped therapeutic practice, yet unmet needs persist in durability of response, safety profiles, real-world accessibility, and affordability. This introduction frames the evolving clinical, commercial, and regulatory contexts that are influencing care pathways for patients with neovascular age-related macular degeneration and pathologic myopia.
Clinicians and payers alike are grappling with treatment paradigms that balance injection frequency, anatomical outcomes, and patient adherence. At the same time, novel modalities and combination strategies are emerging to extend durability, reduce treatment burden, and address subpopulations with refractory disease or specific lesion morphologies. Consequently, stakeholders from device and pharmaceutical sponsors to providers and health systems must align around evidence generation, health economics, and delivery models that support sustained patient benefit. This section establishes the clinical imperatives and market forces that underpin the subsequent analysis, setting expectations for how therapeutic innovations and system-level shifts will influence clinical practice and commercial strategy.
Exploring how therapeutic innovation, advanced imaging, combination strategies, and real-world evidence are reshaping clinical and commercial dynamics in CNV care
The landscape for CNV is undergoing transformative shifts driven by converging scientific advances, evolving standards of care, and shifting payer expectations. Biologic engineering has enabled more potent and longer-acting anti-VEGF agents while refinements in formulation and delivery are moving the field toward less frequent dosing and potentially sustained-release approaches. These scientific developments are complemented by advances in imaging and disease monitoring, where high-resolution OCT and AI-assisted analytics are enabling earlier detection of disease activity and more personalized retreatment schedules.
Simultaneously, combination therapy strategies that pair photodynamic mechanisms with VEGF inhibition are being revisited to address specific lesion subtypes and to potentially reduce overall treatment burden. Real-world evidence is increasingly informing label expansions and reimbursement discussions, influencing adoption patterns across hospital systems and ambulatory settings. On the commercial front, manufacturers are adapting launch strategies to emphasize comparative effectiveness and differentiated value propositions, while providers are optimizing care delivery across hospital pharmacies, retail channels, and specialty clinics. Taken together, these shifts are expanding therapeutic choices and prompting stakeholders to reassess clinical pathways, evidence needs, and value communication.
Assessing the strategic implications of evolving U.S. tariff environments on supply chain resilience, sourcing strategies, and access dynamics within CNV treatment channels
Policy changes and tariff scenarios within the United States have become material considerations for supply chain planning and pricing strategies in ophthalmology. Adjustments to import tariffs on pharmaceutical components and medical devices influence manufacturing location decisions, packaging, and distribution economics, requiring manufacturers to reevaluate sourcing strategies and contract terms to preserve margin and maintain predictable supply to providers.
As a result, there is greater emphasis on nearshoring options, regional manufacturing partnerships, and supply chain redundancy to mitigate exposure to tariff-driven cost volatility. Payers and providers are increasingly attentive to total cost of care and may shift procurement preferences toward therapies that demonstrate clear economic and clinical value in the context of higher logistics costs. For companies, proactive scenario planning that models tariff impacts across distribution channels and end users-hospital pharmacies, retail pharmacies, ambulatory surgical centers, and ophthalmology clinics-can inform pricing approaches, rebate structures, and contracting negotiations. In this environment, transparent communication about cost drivers and collaborative approaches to patient access programs are essential to sustain utilization and support adherence to guideline-driven care.
Delivering strategic clarity through treatment, drug class, disease, lesion, therapy line, distribution, and end-user segmentation insights that inform targeting and development
A nuanced understanding of segmentation is critical to target clinical development and commercial efforts effectively. Treatment type remains foundational, with anti-VEGF therapy representing a core category inclusive of agents such as aflibercept, bevacizumab, brolucizumab, conbercept, and ranibizumab, each offering distinct efficacy, durability, and safety considerations. Combination approaches that integrate photodynamic therapy with anti-VEGF are being explored to address select lesion morphologies and to potentially reduce treatment frequency, while standalone photodynamic therapy using verteporfin retains specific niche indications.
Drug class distinctions between fusion proteins and monoclonal antibodies influence mechanism of action, immunogenicity risk, and production platforms, shaping development strategies and regulatory positioning. Disease-type segmentation separates clinical approaches for neovascular age-related macular degeneration and pathologic myopia, which present different natural histories, patient demographics, and outcome priorities. Lesion type-classic, mixed, and occult CNV-affects therapeutic responsiveness and imaging-guided decision-making. Line-of-therapy considerations spanning first, second, and third lines dictate clinical trial design and commercial messaging, as refractory populations may require differentiated value propositions. Finally, distribution channels and end-user environments, from hospital and retail pharmacies to ambulatory surgical centers and ophthalmology clinics, each present unique procurement behaviors, reimbursement pathways, and operational constraints that must be aligned with market access strategies.
Unpacking the distinctive regional drivers across the Americas, Europe–Middle East–Africa, and Asia–Pacific that influence access, reimbursement, and adoption pathways in CNV care
Regional dynamics play a pivotal role in shaping clinical adoption, regulatory pathways, and commercial approaches. In the Americas, care delivery is driven by a combination of academic referral centers, community ophthalmology practices, and integrated health systems that prioritize evidence-based adoption of long-acting therapies and cost-effectiveness in procurement decisions. Reimbursement frameworks and payer negotiations heavily influence formulary placement and access programs, while real-world registries and longitudinal datasets increasingly inform local practice.
Across Europe, the Middle East, and Africa, heterogeneity in regulatory environments and health system structures yields a mosaic of uptake patterns; centralized procurement in some markets contrasts with decentralized provider-driven adoption in others, necessitating flexible market-entry and pricing strategies. In the Asia-Pacific region, rapid demographic aging, expanding private and public ophthalmic infrastructure, and emergent local biotherapeutic development are accelerating demand for advanced CNV therapies, while regional manufacturing capacity and regulatory harmonization efforts are shaping supply dynamics. Each geography presents distinct clinical priorities, distribution complexities, and stakeholder expectations that should guide tailored launch plans and evidence generation strategies.
Examining competitive differentiation, partnership strategies, and evidence priorities among leading companies to advance therapeutic advantage in CNV management
Competitive dynamics in the CNV therapeutic area are characterized by a mix of established biologics, emergent long-acting agents, and evolving combination strategies, with companies differentiating through clinical performance, dosing convenience, and demonstrated value in real-world settings. Market participants are prioritizing investments in formulation science, sustained-release delivery systems, and head-to-head clinical comparisons to substantiate claims of extended durability and improved anatomical outcomes.
Strategic partnerships, licensing arrangements, and co-development agreements are increasingly common as firms seek complementary capabilities in biologics manufacturing, ophthalmic device delivery, and regional commercialization. Portfolio decisions are being informed by mechanistic differentiation between fusion proteins and monoclonal antibodies, as well as by evidence addressing lesion subtype responsiveness and treatment-resistant populations. Additionally, organizational focus on health economics, outcomes research, and payer engagement is growing, reflecting the need to align clinical innovation with demonstrable cost-effectiveness and patient-centric endpoints to secure favorable reimbursement and long-term uptake.
Implementing targeted clinical evidence, supply resilience, and partnership-driven commercialization tactics to accelerate access and distinguish therapeutic offerings in CNV care
Industry leaders should pursue a set of actionable moves to navigate scientific, commercial, and policy complexities while accelerating patient access to effective treatments. First, aligning clinical development with robust real-world evidence generation will strengthen health economic arguments and support reimbursement discussions; studies should be designed to capture durability, quality-of-life, and resource utilization outcomes that matter to payers and providers. Second, optimizing manufacturing and supply chain footprints to address tariff-induced volatility will reduce exposure to cost shocks and support reliable distribution across hospital and retail channels.
Third, segmenting go-to-market strategies by disease type, lesion morphology, and line of therapy will enable targeted messaging and clinical trial design, ultimately improving conversion among ophthalmology clinics, ambulatory surgical centers, and hospital systems. Fourth, forming strategic alliances-whether for delivery technologies, regional commercialization, or data analytics-can accelerate time-to-market and broaden access. Finally, investing in provider education, digital monitoring tools, and patient support programs will enhance adherence, demonstrate real-world value, and differentiate offerings in a crowded therapeutic landscape.
Outlining a rigorous, multi-source research methodology combining clinical evidence synthesis, expert engagement, and policy analysis to ensure transparent and actionable findings
The research methodology underpinning this analysis combined systematic literature review, synthesis of peer-reviewed clinical data, expert interviews with retina specialists and health system decision-makers, and an assessment of regulatory and reimbursement policy developments up to mid-2024. Clinical efficacy and safety insights were triangulated from randomized controlled trials, registries, and post-marketing surveillance reports to ensure a comprehensive view of therapeutic performance across lesion types and patient subgroups.
Commercial and access conclusions were informed by interviews with commercial leaders, formulary decision-makers, and supply chain specialists, augmented by review of public regulatory filings and guidance documents. Segmentation analysis was conducted by mapping treatment types, drug classes, disease types, lesion morphology, lines of therapy, distribution channels, and end-user settings to observed clinical practices and procurement behaviors. Where applicable, sensitivity checks and scenario analyses were used to assess implications of policy shifts and supply chain changes. The methodology prioritized transparency and reproducibility, enabling stakeholders to trace conclusions back to primary evidence and expert input.
Concluding synthesis emphasizing integration of clinical innovation, real-world evidence, and operational resilience as critical levers for long-term success in CNV management
In conclusion, choroidal neovascularization management is at a strategic inflection point where therapeutic innovations, evidence generation, and supply chain resilience converge to define future care pathways. Advances in anti-VEGF therapies and combination approaches are expanding clinical options, while imaging and data-driven monitoring enable more personalized and efficient retreatment strategies. At the same time, policy shifts and tariff considerations are prompting stakeholders to rethink sourcing and distribution to ensure uninterrupted access and sustainable economics.
For decision-makers across clinical, commercial, and policy domains, the imperative is to integrate high-quality clinical data with real-world outcomes, align development and launch plans to segmented patient needs, and build operational agility into manufacturing and distribution networks. By doing so, organizations can improve patient outcomes, demonstrate value to payers, and secure a competitive position in an increasingly complex and dynamic landscape.
Note: PDF & Excel + Online Access - 1 Year
Table of Contents
193 Pages
- 1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Segmentation & Coverage
- 1.3. Years Considered for the Study
- 1.4. Currency
- 1.5. Language
- 1.6. Stakeholders
- 2. Research Methodology
- 3. Executive Summary
- 4. Market Overview
- 5. Market Insights
- 5.1. Integration of artificial intelligence image analysis in early CNV detection and monitoring
- 5.2. Development of sustained-release intravitreal implants to reduce treatment burden in CNV patients
- 5.3. Emergence of gene editing therapies targeting vascular endothelial growth factor pathways for CNV
- 5.4. Increasing uptake of biosimilar anti-VEGF agents to improve affordability and access for CNV care
- 5.5. Adoption of teleophthalmology platforms for remote monitoring and management of CNV progression
- 6. Cumulative Impact of United States Tariffs 2025
- 7. Cumulative Impact of Artificial Intelligence 2025
- 8. Choroidal Neovascularization Market, by Treatment Type
- 8.1. Anti-Vegf Therapy
- 8.1.1. Aflibercept
- 8.1.2. Bevacizumab
- 8.1.3. Brolucizumab
- 8.1.4. Conbercept
- 8.1.5. Ranibizumab
- 8.2. Combination Therapy
- 8.3. Photodynamic Therapy
- 9. Choroidal Neovascularization Market, by Drug Class
- 9.1. Fusion Proteins
- 9.2. Monoclonal Antibodies
- 10. Choroidal Neovascularization Market, by Disease Type
- 10.1. Neovascular Amd
- 10.2. Pathologic Myopia
- 11. Choroidal Neovascularization Market, by Lesion Type
- 11.1. Classic Cnv
- 11.2. Mixed Cnv
- 11.3. Occult Cnv
- 12. Choroidal Neovascularization Market, by Line Of Therapy
- 12.1. First Line
- 12.2. Second Line
- 12.3. Third Line
- 13. Choroidal Neovascularization Market, by Distribution Channel
- 13.1. Online
- 13.2. Offline
- 14. Choroidal Neovascularization Market, by End User
- 14.1. Ambulatory Surgical Centers
- 14.2. Hospitals
- 14.3. Ophthalmology Clinics
- 15. Choroidal Neovascularization Market, by Region
- 15.1. Americas
- 15.1.1. North America
- 15.1.2. Latin America
- 15.2. Europe, Middle East & Africa
- 15.2.1. Europe
- 15.2.2. Middle East
- 15.2.3. Africa
- 15.3. Asia-Pacific
- 16. Choroidal Neovascularization Market, by Group
- 16.1. ASEAN
- 16.2. GCC
- 16.3. European Union
- 16.4. BRICS
- 16.5. G7
- 16.6. NATO
- 17. Choroidal Neovascularization Market, by Country
- 17.1. United States
- 17.2. Canada
- 17.3. Mexico
- 17.4. Brazil
- 17.5. United Kingdom
- 17.6. Germany
- 17.7. France
- 17.8. Russia
- 17.9. Italy
- 17.10. Spain
- 17.11. China
- 17.12. India
- 17.13. Japan
- 17.14. Australia
- 17.15. South Korea
- 18. Competitive Landscape
- 18.1. Market Share Analysis, 2024
- 18.2. FPNV Positioning Matrix, 2024
- 18.3. Competitive Analysis
- 18.3.1. Kodiak Sciences
- 18.3.2. F. Hoffmann-La Roche Ltd.
- 18.3.3. Novartis AG
- 18.3.4. Regeneron Pharmaceuticals Inc.
- 18.3.5. Bayer AG
- 18.3.6. Bausch Health
- 18.3.7. Biogen, Inc.
- 18.3.8. Bausch + Lomb Corporation
- 18.3.9. Regeneron Pharmaceuticals Inc.
- 18.3.10. Genentech, Inc.
- 18.3.11. Kodiax Pharmaceuticals
- 18.3.12. Iveric Bio
- 18.3.13. Chugai Pharmaceutical Co., Ltd.
- 18.3.14. PulseSight Therapeutics
- 18.3.15. Adverum Biotechnologies
- 18.3.16. Santen Pharmaceutical Co. Ltd.
- 18.3.17. Sandoz Inc.
- 18.3.18. Clearside Biomedical
- 18.3.19. Samsung Bioepis.
- 18.3.20. Apellis Pharmaceuticals, Inc.
- 18.3.21. Astellas Pharma Inc.
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
